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Integration-deficient lentiviruses (IdLVs) deliver genes effectively to tissues but are lost rapidly
from dividing cells. This property can be harnessed to express transgenes transiently to ma-
nipulate cell biology. Here, we demonstrate the utility of short-term gene expression to improve
functional potency of hematopoietic stem and progenitor cells (HSPCs) during transplanta-
tion by delivering HOXB4 and Angptl3 using IdLVs to enhance the engraftment of HSPCs.
Constitutive overexpression of either of these genes is likely to be undesirable, but the tran-
sient nature of IdLVs reduces this risk and those associated with unsolicited gene expression
in daughter cells. Transient expression led to increased multilineage hematopoietic engraft-
ment in in vivo competitive repopulation assays without the side effects reported in constitutive
overexpression models. Adult stem cell fate has not been programmed previously using IdLVs,
but we demonstrate that these transient gene expression tools can produce clinically relevant
alterations or be applied to investigate basic biology. © 2017 ISEH – Society for Hematology
and Stem Cells. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Improved tissue engineering and reprogramming of adult and
pluripotent stem cells could be achieved through con-
trolled, time-restricted gene expression. Application of
transcription factors and other genes involved in cell fate de-
cisions often requires transient signals that are difficult to
control with current technologies without applying exoge-
nous chemicals to induce or repress promoter activity. Here,
we demonstrate the utility of short-term gene expression from
a viral delivery vector to alter progenitor cell behavior using
hematopoietic stem and progenitor cells (HSPCs) as a model
system.
Inherited and acquired blood disorders are treated by HSPC
transplantation. Altering cellular characteristics, such as rep-
lication, homing, and engraftment, could improve clinical
outcome; the ability to expand cell populations would be ben-
eficial, especially when the number of donor HSPCs is limited.
Many genes have been proposed to assist expansion of cell
populations while maintaining the progenitor pool, but long-
term overexpression could be detrimental [1]. Lentiviral vectors
can deliver genes efficiently to a large range of cells for bi-
ological experimentation or for gene therapy [2], where they
are showing promise in clinical trials [3]. However, conven-
tional lentiviral vectors integrate their transgene payload
permanently into the host cell’s genome, which is not desir-
able in the setting of transient cell fate programming.
Integration-deficient lentiviral vectors (IdLVs) deliver a genetic
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payload, but, due to mutations within the viral integrase gene
[4], cannot mediate stable integration of the reverse-transcribed
proviral DNA into the host cells’ chromosomes. In dividing
cells, this results in dilution of episomal DNA with expres-
sion of the transgene rapidly falling to undetectable levels
[5].
Here, the ability of IdLVs to influence HPSC behavior was
assessed in HSPCs using transplantation as the functional read-
out. These vectors were used for the transient expression of
two genes involved in blood progenitor cell maintenance and
expansion, human Homeobox B4 (HOXB4) and murine
Angiopoietin-like 3 (Angptl3), and to compare them with stan-
dard, integration-proficient lentiviral vectors (IpLVs). HOXB4
has been reported previously to maintain stem cell function
during cell expansion [6,7] and was therefore applied using
IdLVs to test whether this approach can facilitate biologi-
cally relevant changes in cells without the drawbacks of
integrating vectors [8] or the need for exogenous drugs to
control promoter activity. Although it is unlikely that HOXB4
would be useful in a clinical setting, the application of the
protein and the resulting effect on HSPC expansion is well
understood, making it useful for these proof-of-concept ex-
periments. Angptl3 is less characterized, but it has shown
promise in expanding HSPC populations when applied as a
protein or permanently expressed in cells [9–11]; therefore,
it was also delivered using IdLVs to measure the biological
effects of its short-term expression in cells.
Methods
Virus production
Vesicular stomatis virus G (VSV-G)-pseudotyped pLBid.nlsCre.
SF.mCherry [12], pRRL.PPT.SF.co-HOXB4.bPRE4*, and
pRRL.PPT.SF.co-Angptl3.bPRE4* vectors were produced using
second-generation packaging plasmids as described previously [13]
both with and without the D64V integrase mutation [4] to package
IdLVs and IpLVs, respectively. IpLVs expressing a Venus reporter
gene were used as control vectors.
LSK cell isolation and growth
HSPC Lin− Sca-1+ C-kit+ (LSK) cells were separated after isola-
tion of bone marrow (BM) cells by flushing mouse femur and tibia
bones. Harvested cells were stained with the lineage antigens CD3,
CD45R (B220), CD11b, Gr-1 (Ly-6G/C), 7–4, and Ter-119. Lin−
cells were isolated using the mouse Lineage Cell Depletion Kit
(Miltenyi Biotec) following the manufacturer’s recommendations.
Lin− isolated cells were stained with streptavidin-fluorescein
isothiocyanate (FITC), phycoerythrin (PE) Ly-6A/E (Sca-1), and
allophycocyanin (APC) CD117 (c-kit) (all obtained from BD Bio-
sciences), and the LSK population was isolated in a MoFlo XDP
sorter (Beckman Coulter) (gating strategy shown in Supplementa-
ry Figure E1, online only, available at www.exphem.org). Cells were
resuspended at 5 × 105 cells/mL in StemSpan SFEM (StemCell Tech-
nologies), supplemented with 0.5% penicillin–streptomycin, murine
stem cell factor (mSCF; 300 ng/mL), human thrombopoietin (hTPO;
100 ng/mL, R&D Systems), and FLT3-L (100 ng/mL; Miltenyi
Biotec). After 12 hours of prestimulation at 37°C, 5% CO2 fully hu-
midified air, LSKs were transduced with vectors at various
multiplicities of infection (MOIs) for 24 hours by adding virus to
the medium.
In vitro colony-forming unit assays
A total of 100 LSKs were seeded in MethoCult GF-M3534 medium
(StemCell Technologies) in triplicate in 35-mm plastic plates and
cultured at 37°C, 5% CO2, fully humidified air. After 7 days, colony
numbers were scored.
In vitro cre-loxP experiments
K562 cells were transduced with SF91.LoxP.MCSI.eGFP.
LoxP.EBFP2.bPre vector particles at low MOI, aiming for one vector
copy per cell (<10% green fluorescent protein-positive [GFP+]). These
cells were expanded, sorted for GFP fluorescence, and serially diluted
to select clones. This target cell line was then transduced with IpLV
or IdLV pLBid.nlsCre.SF.mCherry and levels of enhanced GFP
(eGFP), blue fluorescent protein (BFP), and mCherry measured by
flow cytometry over time.
In vivo cre-loxP experiments
Donor LSK cells were isolated from ROSA26-eYFP mouse BM.
After transduction (MOI 100), 2 × 104 CD45.1-LSK cells were in-
jected into the tail veins of lethally irradiated C56BL/6J recipients
(6 Gy/4 Gy split-dose over 2 days). Results were obtained from three
mock-transduced mice or groups of four mice receiving IpLV- or
IdLV-transduced cells.
Reverse transcriptase polymerase chain reaction
Levels of HOXB4 were measured by isolating RNA from 1 × 104
Lin− cells (Qiagen, RNEasy minikit). RNA was treated with DNAse
then reverse transcribed. Reverse transcriptase polymerase chain re-
action (RT-PCR) for HOXB4 or a gapdh control was performed using
the Applied Biosystems gapdh primer set Mm99999915_g1 or the
following primers specific to PRE element present in the 3′
untranslated region of the HOXB4 RNA: 5′-TGTGTTTG
CTGACGCAACC-3′ and 5′-CCGACAACACCACGGAATT-3′ with
cycling conditions 95°C for 15 seconds at 60°C for 1 minute for
40 cycles.
Vector-specific PCR and titration of virus preparations
DNA from different organs was extracted using a DNeasy Blood
and Tissue kit (Qiagen). Titer and vector copy number (VCN) were
calculated by real-time PCR (ABI Prism 7000) with primer/probe
combinations to WPRE and titin [14] or to the long terminal repeat:
U5-F-5′-TCTGGCTAACTAGGGAACCCA-3′ and U5-R-5′-
CTGACTAAAAGGGTCTGAGG-3′ with SYBR green using cycling
conditions as above. Alternatively, the same primers were used in
a standard PCR reaction and the products separated by electropho-
resis in a 2% agarose gel.
Statistical analyses were performed using GraphPad Prism
software.
In vivo competitive repopulation assay
C57BL/6J(CD45.2) mice were used as recipients and as a source
of BM competitor cells and B6.SJL-PtprcaPep3b/BoyJ(CD45.1) mice
as LSK cell donors (Fig. 1). After transduction, 2 × 104 CD45.1-
LSK cells and 106 freshly harvested CD45.2 total BM cells were
injected into the tail veins of lethally irradiated recipients (6 Gy/4 Gy
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split-dose over 2 days). Results were obtained from four separate
reconstitution assays with the following numbers of animals in each
group in total: Venus-IpLV100, n = 7; HOXB4-IdLV200, n = 6;
HOXB4-IdLV500, n = 6; HOXB4-IpLV100, n = 8; Angptl3-
IdLV500, n = 3; and Angptl3-IpLV100, n = 7.
The Institutional Research Ethics Committee approved all animal
procedures (Institute of Child Health, UCL) performed under UK
Home Office License PPL70/7024.
Flow cytometry
Chimerism of CD45.1 cells in peripheral blood (30, 60, and 90 days
after transplantation) and of BM and spleen collected at the end of
the 90-day experiment were analysed by flow cytometry (LSRII,
BDBiosciences) with antibodies targeting CD45.1 antigen com-
bined with markers for different blood cell lineages. The same
machine was used to measure expression of enhanced yellow flu-
orescent protein (eYFP), eGFP, BFP, and mCherry using untransduced
cells to set the gating strategy.
Results
The expression kinetics of genes delivered with IdLVs and
IpLVs were determined in vitro in an immortalized K562 cell
model. A gamma-retroviral vector, SF91 loxP MCSI eGFP
loxP eBFPco bPRE, was used to insert a construct contain-
ing an eGFP marker gene flanked by loxP sites and was
excised when cre recombinase was expressed in the cells, con-
currently initiating expression of a downstream BFP. IpLVs
and IdLVs were used to deliver the cre recombinase gene
coexpressed from a bidirectional promoter with mCherry flu-
orescent protein [12] (Supplementary Figure E2A, online only,
available at www.exphem.org). Delivery of cre recombinase
with either vector at increasing MOIs reduced eGFP expres-
sion progressively over time while BFP expression
commenced. The lack of detectable mCherry expression from
IdLVs after 4 days demonstrated the transient nature of the
gene delivery to these dividing cells, but short-term
Figure 1. The in vivo competitive repopulation assay. BM cells were obtained by flushing femurs and tibias of C57BL/6J CD45.1 mice before staining with
the lineage antigens CD3, CD45R (B220), CD11b, Gr-1 (Ly-6G/C), 7–4, and Ter-119. Lin− cells were isolated using the mouse Lineage Cell Depletion Kit
(Miltenyi Biotec) following the manufacturer’s recommendations. Lin− isolated cells were stained with streptavidin-FITC, PE Ly-6A/E (Sca-1), and APC
CD117 (c-kit) (all obtained from BD Biosciences), and the LSK population was isolated in a MoFlo XDP sorter (Beckman Coulter). Cells were resus-
pended at 5 × 105 cells/mL in StemSpan SFEM (StemCell Technologies) supplemented with 0.5% penicillin–streptomycin, mSCF (300 ng/mL), hTPO (100 ng/
mL, R&D Systems), and FLT3-L (100 ng/mL; Miltenyi Biotec) and cultured overnight before and after overnight culture and transduced for 24 hours with
IdLVs or IpLVs at different MOIs. IdLV or IpLV versions of lentiviral vectors expressing a HOXB4 or Angptl3 or IpLV fluorophore (Venus, control) were
used in this study. Self-inactivating vectors were produced with a ΔU3-deleted 3′ long-terminal repeat, with the transgene under the control of the internal
spleen focus-forming virus long-terminal repeat promoter element. Transduced LSK cells were harvested the next day, and 2 × 104 of them were injected
into the tail veins of lethally irradiated C57BL/6J CD45.2 recipient mice (split dose of 6 Gy and 4 Gy over 2 consecutive days, gamma irradiated using a
caesium-137 source, dose rate 3 Gy/minute). One million freshly harvested CD45.2 total BM cells were injected alongside the CD45.1 donor LSKs as com-
petitors. cPPT = Central polypurine tract; IRES = internal ribosomal entry site; PRE = attenuated post-transcriptional regulatory element; U5, R, and (Δ)U3 = (self-
inactivating) long-terminal repeats; Ψ = packaging signal.
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expression of cre produced a permanent alteration in eGFP/
BFP production. The same result was achieved with integrating
IpLVs, in which expression of cre/mcherry was stable over
the 10-day period (Supplementary Figure E2B, online only,
available at www.exphem.org). The use of a higher MOI (50)
of IpLVs appeared to be toxic (data not shown), probably due
to higher expression levels from IpLVs [15].
To determine whether a brief pulse of expression could
produce an equivalent permanent change in vivo, a similar
system in a mouse model in which cre recombinase induces
eYFP expression in cells was tested [16]. Transduction of LSK
BM cells from target mice with IpLVs or IdLVs expressing
cre before transplantation into YFP-negative recipient mice
gave rise to expression of eYFP-positive cells in the BM space
(Fig. 2A), whereas the YFP locus in mock-transduced donor
cells was not activated, and the marker gene was not ob-
served in recipients. After 6 months, the cre gene delivered
by IpLVs was maintained in the host cells’ genome, but IdLV
was not detectable by PCR in three of four mice. The very
faint signal in the fourth mouse reveals a possible back-
ground integration event or PCR contamination (Fig. 2B).
With the cre-lox experiments providing clear evidence that
transduction of cells with IdLVs can result in measurable
changes in cells, the system was tested in mouse Lin− BM
HSPCs to observe the expression kinetics of the HOXB4 tran-
scription factor. Levels of HOXB4 RNA reduced to background
signal in cells transduced with IdLV after 3 days growing in
liquid culture. HOXB4 RNA was produced from the IpLVs
until the last time-point after 22 days in culture, confirming
the limited duration of expression from IdLV in HSPC
(Fig. 2C), compared with standard integrating vectors.
LSK HSPC cells were harvested from mouse BM and
transduced with IpLVs and IdLVs to deliver HOXB4 at dif-
ferent MOIs to determine whether transient expression of the
Figure 2. IdLV transduction of BM cells provides transient gene expression in vitro and in vivo. LSK cells were isolated from BM harvested from ROSA26-
eYFP mice that contain an eYFP gene at the ROSA26 locus that is expressed upon exposure to cre-recombinase, which removes a disruptive neomycin (Neo)
cassette [16]. Cells were transduced with IdLVs or IpLVs encoding cre recombinase at an MOI of 100 before injecting into lethally irradiated wild-type (YFP-
negative) recipients. (A) Analysis of recipient BM 6 months later revealed YFP-positive cells engrafted after cre recombinase expression from IdLVs and
IpLVs. (B) Vector-specific PCR confirmed the long-term persistence for vector in IpLV samples, but not IdLV. (C) Lin− cells were transduced with IdLVs or
IpLVs expressing HOXB4 and grown in liquid culture. RT-PCR showed that HOXB4 expression from IdLVs can be observed for up to 3 days when cells are
in culture, whereas IpLVs expressed the gene until the end of the experiment (22 days). Primers specific for gapdh were used as a positive control for the
RT-PCR. blank = Non-template PCR control; mock = mock-transduced cells.
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gene can maintain or expand HSPC in vitro. In most cases,
this generated limited expansion of progenitor cells from
mouse LSK populations as expected (Supplementary
Figure E3A, online only, available at www.exphem.org) [17].
However, when grown in liquid culture, which normally
induces HSPC differentiation and reduces self-renewal ac-
tivity [18], IdLV-mediated delivery of HOXB4 and Angptl3
resulted in a trend toward enhanced maintenance of differ-
entiation potential when cultured over 7 days and tested in
clonogenic assays compared with controls (Supplementary
Figure E3B, online only, available at www.exphem.org).
Despite inherent assay variability, IdLV produced similar bi-
ological effects to IpLV, warranting further testing in vivo.
LSK cells from congenic C57BL/6J CD45.1+ mice were
isolated to high purity (Supplementary Figure E1, online only,
available at www.exphem.org) and transduced with IpLV and
IdLV to deliver genes encoding HOXB4 or Angptl3 or a Venus
IpLV fluorophore gene control at MOIs between 100 and 500
(based on PCR, not a functional titer). IdLV transcriptional
activity was lower than that for IpLV (data not shown and
as reported previously [15]), so increased IdLV concentra-
tions were used to compensate [19].
Using a competitive repopulation assay to determine the
engraftment potential and fitness of cultured HSPCs (out-
lined in Fig. 1), ectopic expression of HOXB4 or Angptl3
improved engraftment of CD45.1 donor cells in BM com-
pared with Venus controls (Fig. 3A). Constitutive
overexpression of HOXB4 (HOXB4-IpLV) resulted in the
greatest increase in chimerism of donor cells (11.9-fold median
increase over Venus transduction, p < 0.001). Transient
HOXB4 expression from IdLV resulted in a visible trend
toward increased engraftment, but did not reach statistical sig-
nificance (2.4- and 3.4-fold median increase in engraftment
at an HOXB4-IdLV[MOI] 200 and 500, respectively).
However, both the integrating and versions of the Angptl3-
containing vectors were able to increase HSPC engraftment
significantly, resulting in 7.3- and 9.3-fold increased levels
of donor chimerism over controls for IdLVs and IpLVs, re-
spectively (p < 0.05, p < 0.01, Fig. 3A). VCN analysis in BM
cells (Fig. 3B) showed that IpLV proviral DNA was inte-
grated and maintained in BM as expected, whereas IdLV was
undetectable or present in negligible amounts after 90 days,
despite using higher MOIs (reduction in VCN vs. IpLV: 56-
or 60-fold [HOXB4-IdLV200/500, p < 0.001] or 13-fold
[Angptl3-IdLV500, p < 0.05]). Similar improvements in en-
graftment were observed in the spleen and peripheral blood
of these mice (Fig. 3C and 3D).
Peripheral blood from these transplanted animals was moni-
tored over 3 months, with results mirroring engraftment
patterns in BM (Fig. 3E). Stable engraftment was apparent
in all samples, with Angptl3-transduced samples showing the
least decline in chimerism.
Compared with controls, increased levels of CD45.1 donor
cells were observed across multiple hematopoietic lineages
(T, B, and myeloid cells) in the peripheral blood 3 months
after transplantation, demonstrating that multipotent HSPCs
were transduced equally by IpLVs and IdLVs (Fig. 4A).
Constitutive overexpression of HOXB4 has been shown
previously to perturb HSPC differentiation toward the myeloid
lineages [20,21]. Lineage distribution of the graft within BM
of IpLV-HOXB4 and IpLV-Angptl3 mice was altered sig-
nificantly compared with controls (p < 0.01), but, importantly,
this aberrant differentiation was rescued in IdLV-transduced
grafts (Fig. 4B). T-, B-, or myeloid cell lineage skewing was
not observed in the spleen or peripheral blood with any vector
(Fig. 4C and 4D).
IdLV-mediated delivery of HOXB4 and Angptl3 into
HSPCs appeared to have no permanent detrimental effects
upon the differentiation capacity of these cells but, particu-
larly in the case of transient delivery of Angptl3, was sufficient
to program HSPC biology to elicit enhanced engraftment ca-
pacity in a clinically relevant transplantation model.
Discussion
Integration-deficient lentiviral vectors can be used to express
a gene in dividing cells, including HSPCs, for less than a week,
as demonstrated by in vitro and in vivo experiments. This is
sufficient to produce a clear biological response to transient
expression of cre recombinase as well as to transcription
factors.
Transient gene delivery of HOXB4 and Angptl3 to HSPC
using IdLVs resulted in improved multi-organ engraftment
of the LSK cells, demonstrating that short-term expression
of these genes can be protective of the pro-differentiation effect
of culturing HSPCs. When expressing Angptl3, IdLV pro-
duced similar benefits as the integrating vector, albeit at a
higher MOI, potentially due to the secreted nature of the
protein promoting more widespread effects [10]. Interest-
ingly, Angptl3 expression elicited greater chimerism of treated
cells in this assay than the more extensively tested HOXB4
gene. This confirms the potential of Angptl3 for HSPC ex-
pansion and the need for greater understanding of this protein
and continued testing of the angiopoietin-like gene family
[22–24]. However, the increasing trend toward enhanced HSPC
engraftment observed with short-term HOXB4 expression is
consistent with the protein’s dose-dependent mode of action
[25], and the optimal MOI may not have been reached. Al-
though not statistically significant, a reproducible twofold
increase in cell numbers would be clinically relevant.
Post-transplantation reconstitution kinetics can be criti-
cal for survival, with the aim of minimizing the period of time
in which a patient is immunocompromised and susceptible
to bleeding and anemia. Early and late progenitor compart-
ments are likely responsible for driving early waves of
hematopoietic reconstitution, and the goal was to under-
stand the overall effect on the whole LSK population including
these and, potentially, long-term repopulating cells to improve
BM cell engraftment after transplantation. The experiments
described here were not designed to characterize which cells
within the transduced LSK population were modified by IdLV
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Figure 3. Transient delivery of HOXB4 and Angptl3 increases long-term donor cell chimerism in BM, spleen, and peripheral blood cells. IpLVs or IdLVs
expressing HOXB4 or Angptl3 at different MOIs (100–500) or a control IpLV expressing the fluorophore Venus were used to transduce CD45.1 donor cells,
which were transplanted into CD45.2 mice in an in vivo competitive repopulation assay. (A) BM cells from CD45.2 recipients were analyzed by flow cytometry
to determine chimerism of donor CD45.1 cells at 90 days after injection. There was a statistical difference between samples over the whole group for BM
(p < 0.0001, percentage data normalized by inverse-sine transformation followed by one-way analysis of variance [ANOVA]). *p < 0.5, **p < 0.01, ***p < 0.001
(Šidák’s post hoc multiple comparison test vs. Venus IpLV 100). Bar shows the median value with fold increase in median values of samples compared with
the control (top). (B) Real-time PCR vector copy number analysis in BM cells after 90 days. Error bars indicate mean value ±95% confidence intervals.
Overall p < 0.0001, one-way ANOVA of copy numbers normalized by log transformation; *p < 0.5, ***p < 0.001, Šidák’s post hoc multiple-comparisons
test for comparisons between HOXB4 vectors and, separately, between Angptl3-treated mice. (C) Spleen and (D) peripheral blood from CD45.2 recipients
were analyzed by flow cytometry to determine chimerism of transduced donor cells. There was a statistical difference between samples over the whole group
for spleen cells collected at 90 days, p < 0.0001. Differences in chimerism in peripheral blood between groups did not reach statistical significance, except
for HOXB4-IpLV100 versus Venus-IpLV100 (percentage data normalized by inverse-sine transformation followed by one-way ANOVA). *p < 0.5, **p < 0.01,
***p < 0.001, Šidák’s post hoc multiple-comparisons test versus Venus-IpLV 100. (E) CD45.1 chimerism in the peripheral blood was measured at three time
points over the 90-day period. Data shown are the median value; error bars indicate interquartile range.
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transduction. Transient gene expression was shown to improve
total HSPC engraftment without the relative individual con-
tributions of different progenitor populations.
A pulse of transgene expression from IdLV was there-
fore sufficient to produce biologically relevant changes in stem
cells, but with greatly reduced risk of insertional mutagen-
esis that has caused serious adverse events in gene therapy
clinical trials using IpLVs and gamma-retroviral vectors
[26–28]. Aberrant experimental results or clinical toxicity as-
sociated with high levels of permanent transgene expression
and protein production from integrating vectors could also
be avoided with IdLVs. Low-level random integration can
occur in IdLVs, but at rates approaching four logs lower than
integrase-mediated insertions from standard retroviruses
[29–31], and does not always result in a functional gene being
integrated.
Long-term overexpression of HOXB4 in HSPCs skews
commitment to different lineages and is associated with pro-
gression to leukemia [8] Oncogenesis was not observed in
any mice, but lineage distribution of the graft within BM of
IpLV-HOXB4 and IpLV-Angptl3 mice was altered signifi-
cantly compared with controls (p < 0.01); differences observed
in IdLV-treated mice were not statistically significant. This
side effect was not evident in IdLV-transduced grafts dem-
onstrating their utility for time-limited expression of genes
associated with toxicity without resorting to inducible pro-
moters or similar extrinsic control systems that are often
difficult to control robustly in vivo.
Conclusion
IdLVs provide a platform for short-term gene expression,
shown here to be sufficient to influence HSPC characteris-
tics. Such transient expression in any dividing cell type could
be applied in many situations in stem cells that require de-
livery of RNAi constructs, such as “suicide” genes,
recombinases, gene-editing tools, and transcription factors
[32,33]. IdLVs could therefore be used to affect stem cell fate
through reprogramming, direct programming, facilitating dif-
ferentiation, or expanding cells, with minimal long-term impact
on the genome of the target cell or constitutive signaling.
Figure 4. Expression of HOXB4 or Angptl3 from IdLV does not skew lineage differentiation in transduced cells. (A) Representative flow cytometry plots
showing levels of CD45.1 donor-derived T (CD3), B (B220), and myeloid (GR/MAC) cells (upper right quadrant) measured in recipient mouse PBMCs at
90 days after transplantation. The proportion that each lineage contributes to the average total CD45.1 cell population in each group was calculated by flow
cytometry analysis in cells collected from (B) BM, (C) spleen, and (D) peripheral blood. One-way ANOVA on inverse sine-transformed percentage data for
each lineage within each tissue reached significance (p < 0.05) for T-cell and myeloid lineages within BM cells. HOXB4-IpLV100 samples were signifi-
cantly different from Venus IpLV-100 samples (p < 0.01) in the myeloid and T-cell lineages, and Angptl3-IpLV100 had a significantly lower proportion of T
cells than the control (p < 0.01, Dunnett’s post hoc multiple-comparisons test using a 99% confidence interval). n ≥ 3 in each group. Error bars indicate stan-
dard deviation.
ARTICLE IN PRESS
7M.E. Alonso-Ferrero et al. / Experimental Hematology 2017;■■:■■–■■
Other methods also can provide transient protein produc-
tion in this setting [34–38], but the advantage of IdLVs lies
in the efficiency with which they can deliver genes to most
cell types, including many sources of stem cells that divide
slowly during the initial transduction.
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